Literature DB >> 9580377

Endocardial and epicardial ablation guided by nonsurgical transthoracic epicardial mapping to treat recurrent ventricular tachycardia.

E Sosa1, M Scanavacca, A D'Avila, J Piccioni, O Sanchez, J L Velarde, M Silva, B Reolão.   

Abstract

INTRODUCTION: An epicardial site of origin of ventricular tachycardia (VT) may explain unsuccessful endocardial radiofrequency (RF) catheter ablation. A new technique to map the epicardial surface of the heart through pericardial puncture was presented recently and opened the possibility of using epicardial mapping to guide endocardial ablation or epicardial catheter ablation. We report the efficacy and safety of these two approaches to treat 10 consecutive patients with VT and Chagas' disease. METHODS AND
RESULTS: Epicardial mapping was carried out with a regular steerable catheter introduced into the pericardial space. An epicardial circuit was found in 14 of 18 mapable VTs induced in 10 patients. Epicardial mapping was used to guide endocardial ablation in 4 patients and epicardial ablation in 6. The epicardial earliest activation site occurred 107+/-60 msec earlier than the onset of the QRS complex. At the epicardial site used to guide endocardial ablation, earliest activation occurred 75+/-55 msec before the QRS complex. Epicardial mid-diastolic potentials and/or continuous electrical activity were seen in 7 patients. After 4.8+/-2.9 seconds of epicardial RF applications, VT was rendered noninducible. Hemopericardium requiring drainage occurred in 1 patient; 3 others developed pericardial friction without hemopericardium. Patients remain asymptomatic 5 to 9 months after the procedure. Interruption during endocardial pulses occurred after 20.2+/-14 seconds (P = 0.004), but VT was always reinducible and the patients experienced a poor outcome.
CONCLUSION: Epicardial mapping does not enhance the effectiveness of endocardial pulses of RF. Epicardial applications of RF energy can safely and effectively treat patients with VT and Chagas' disease.

Entities:  

Mesh:

Year:  1998        PMID: 9580377     DOI: 10.1111/j.1540-8167.1998.tb00907.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  51 in total

Review 1.  Radiofrequency catheter ablation of ventricular tachycardia.

Authors:  W G Stevenson; E Delacretaz
Journal:  Heart       Date:  2000-11       Impact factor: 5.994

Review 2.  Intrapericardial therapy and diagnosis.

Authors:  David H Spodick
Journal:  Curr Cardiol Rep       Date:  2002-01       Impact factor: 2.931

Review 3.  Telomerase-independent mechanisms of telomere elongation.

Authors:  H Biessmann; J M Mason
Journal:  Cell Mol Life Sci       Date:  2003-11       Impact factor: 9.261

Review 4.  Optimal ablation strategies for different types of ventricular tachycardias.

Authors:  Takumi Yamada; G Neal Kay
Journal:  Nat Rev Cardiol       Date:  2012-05-29       Impact factor: 32.419

5.  Selecting the Appropriate Ablation Strategy: the Role of Endocardial and/or Epicardial Access.

Authors:  Mario Njeim; Frank Bogun
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-12-01

6.  Accuracy of quadratic versus linear interpolation in noninvasive Electrocardiographic Imaging (ECGI).

Authors:  Subham Ghosh; Yoram Rudy
Journal:  Ann Biomed Eng       Date:  2005-09       Impact factor: 3.934

7.  A novel method for preventing phrenic nerve injury during catheter ablation.

Authors:  Eric Buch; Marmar Vaseghi; David A Cesario; Kalyanam Shivkumar
Journal:  Heart Rhythm       Date:  2006-09-22       Impact factor: 6.343

8.  Noninvasive electrocardiographic imaging of arrhythmogenesis: insights from modeling and human studies.

Authors:  Raja N Ghanem
Journal:  J Electrocardiol       Date:  2007 Nov-Dec       Impact factor: 1.438

Review 9.  Transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia.

Authors:  E Sosa; M Scanavacca; A d'Avila
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 10.  Ablation of ventricular fibrillation and tachycardia.

Authors:  Paveljit S Bindra; Francis E Marchlinski
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.